Track topics on Twitter Track topics that are important to you
BEDFORD, Mass., Aug. 11, 2015 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are customized to fit each patient's unique anatomy, announced today financial results for the second quarter ended June 30, 2015.
Recent Accomplishments & Highlights
"We are very pleased with our financial performance in the second quarter along with the growing body of clinical results," said Philipp Lang, MD, MBA, Chief Executive Officer of ConforMIS, Inc. "Our strong product revenue growth this quarter was driven by the progressive adoption of our cruciate-retaining total knee implant, the iTotal CR, and the early contributions from our limited launch of our posterior-stabilized total knee implant, the iTotal PS. We believe ConforMIS' proprietary platform technology for customized joint replacement implants has the potential to disrupt the $15 billion joint replacement market."
Three Months Ended
|Increase / Decrease|
|Rest of World||$3,892||$3,147||745||24%||54%|
Second Quarter 2015 Financial Results
Total revenue increased $8.0 million, or 72% year-over-year, to $19.2 million. Total revenue in the second quarter of 2015 includes royalty revenue of $3.5 million related to lump-sum payments from Wright Medical Group, Inc. ("Wright Medical") and MicroPort Orthopaedics, Inc. ("MicroPort"), paid upon the signing of non-exclusive worldwide license agreements in connection with the settlement of patent litigation. The $5.1 million balance of the payments received from Wright Medical and MicroPort was allocated to deferred revenue and will be recognized over the term of the agreements, of which the last agreement ends in 2031. In addition, MicroPort agreed to an ongoing fixed royalty at a high-single to low-double digit percentage of net sales of patient specific instruments and the associated off-the-shelf knee implants.
Product revenue increased $4.6 million, or 41% year-over-year, to $15.8 million on a reported basis and 50% on a constant currency basis. U.S. product revenue increased $3.8 million, or 48% year-over-year, to $11.9 million, and rest of world product revenue increased $0.7 million, or 24% year-over-year, to $3.9 million on a reported basis and 54% on a constant currency basis. Product revenue from sales of iTotal CR, iUni and iDuo increased $4.0 million, or 36% year-over-year, to $15.2 million. Product revenue from sales of iTotal PS, which we launched on a limited basis in the United States in February 2015, was $0.6 million in the second quarter of 2015.
GAAP gross profit increased $4.5 million, or 110% year-over-year, to $8.6 million, or 45% of revenue, compared to $4.1 million, or 36% of revenue, in the second quarter of 2014. The increase in GAAP gross profit was driven primarily by the addition of royalty revenue from the license agreements. Non-GAAP product gross profit increased $1.0 million, or 25% year-over-year, to $5.1 million, or 32% of product revenue, compared to $4.1 million, or 36% of revenue, in the second quarter of 2014. The decrease in non-GAAP product gross profit margin was driven primarily by the changes in foreign exchange rates compared to last year.
Total operating expenses increased $4.8 million, or 33% year-over-year, to $19.4 million. The increase in expenses was driven primarily by higher sales and marketing and general and administrative expenses, and, to a lesser extent, higher research and development expense compared to the second quarter of 2014.
Net loss was $10.9 million, or $2.51 per share, compared to $10.5 million, or $2.49 per share, for the same period last year.
2015 Financial Guidance
For the full year 2015, the Company expects total revenue in a range of $72 million to $74 million, representing year-over-year growth of 50% to 54% on a reported basis and 57% to 61% on a constant currency basis. The Company's total revenue guidance includes approximately $3 million of currency headwind in our revenue results.
The Company's 2015 revenue guidance assumes the following:
Note on Non-GAAP Financial Measures
In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), this release and the accompanying tables contain certain non-GAAP financial measures that exclude royalty revenue. Non-GAAP information is not a substitute for, and is not superior to, information presented on a GAAP basis. Summary results presented on a GAAP basis, descriptions of our non-GAAP, or operating-basis, financial measures, and reconciliations of operating-basis information to GAAP-basis information are provided in the addendum included with this news release.
The Company provides certain information regarding the Company's financial results or projected financial results on a "constant currency basis." This information estimates the impact of changes in foreign currency rates on the translation of the Company's current or projected future period financial results as compared to the applicable comparable period. This impact is derived by taking the adjusted current or projected local currency results and translating them into U.S. Dollars based upon the foreign currency exchange rates for the applicable comparable period. It does not include any other effect of changes in foreign currency rates on the Company's results or business.
As previously announced, ConforMIS will conduct a conference call and webcast today at 8:30 AM Eastern Time. Management will discuss financial results and strategic matters. To participate in the conference call, please call 877-703-9876 (or 616-548-5612 for international) and use conference ID number 95443100 or listen to the webcast in the investor relations section of the company's website at ir.conformis.com. The online archive of the webcast will be available on the company's website for 30 days.
About ConforMIS, Inc.
ConforMIS is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient's unique anatomy. ConforMIS offers a broad line of customized knee implants and pre-sterilized, single-use instruments delivered in a single package to the hospital. In recent clinical studies, ConforMIS iTotal CR demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. ConforMIS owns or exclusively in-licenses approximately 470 issued patents and pending patent applications that cover customized implants and patient-specific instrumentation for all major joints.
Cautionary Statement Regarding Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for ConforMIS, including statements about ConforMIS's strategy, future operations, future financial position and results and expected market growth, including expectations regarding the potential impact and advantages of using customized implants, total revenue and revenue mix by product and geography, product gross margin and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to our estimates regarding the potential market opportunity for our current and future products, our expectations regarding our sales, expenses, gross margins and other results of operations, and the other risks and uncertainties described in the "Risk Factors" sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent ConforMIS's views as of the date hereof. ConforMIS anticipates that subsequent events and developments may cause ConforMIS's views to change. However, while ConforMIS may elect to update these forward-looking statements at some point in the future, ConforMIS specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing ConforMIS's views as of any date subsequent to the date hereof.
|CONFORMIS, INC. AND SUBSIDIARIES|
|Consolidated Statements of Operations|
|(in thousands, except share and per share data)|
|Three Months Ended June 30,||Six Months Ended June 30,|
|Product||$ 15,763||$ 11,173||$ 30,463||$ 21,972|
|Cost of revenue||10,664||7,097||20,052||14,609|
|Sales and marketing||9,758||7,080||19,338||15,458|
|Research and development||4,317||3,615||8,333||7,193|
|General and administrative||5,355||3,900||11,134||7,848|
|Total operating expenses||19,430||14,595||38,805||30,499|
|Loss from operations||(10,872)||(10,519)||(24,935)||(23,136)|
|Other income and expenses|
|Other income (expense)||208||--||208||--|
|Total other expenses||(9)||(12)||(193)||(39)|
|Loss before income taxes||(10,881)||(10,531)||(25,128)||(23,175)|
|Income tax provision||11||12||21||20|
|Net loss||$ (10,892)||$ (10,543)||$ (25,149)||$ (23,195)|
|Net loss per share - basic and diluted||$ (2.51)||$ (2.49)||$ (5.82)||$ (5.52)|
|Weighted average common shares outstanding - basic and diluted||4,341,784||4,238,837||4,319,334||4,199,746|
|CONFORMIS, INC. AND SUBSIDIARIES|
|Consolidated Balance Sheets|
|(in thousands, except share and per share data)|
|June 30, 2015||December 31, 2014|
|Cash and cash equivalents||$ 14,496||$ 37,900|
|Accounts receivable, net||11,030||9,119|
|Prepaid expenses and other current assets||1,403||1,158|
|Deferred initial public offering costs||4,489||--|
|Total current assets||40,797||55,868|
|Property and equipment, net||10,598||8,696|
|Intangible assets, net||1,119||1,243|
|Other long-term assets||283||280|
|Total assets||$ 57,878||$ 71,278|
|Liabilities and stockholder's equity|
|Current portion of long-term debt||283||272|
|Total current liabilities||15,090||10,832|
|Other long-term liabilities||246||271|
|Commitments and contingencies|
|Convertible preferred stock, $0.00001 par value:|
|Authorized: 53,496,241 shares authorized, 51,055,077 and 50,985,652 shares issued and outstanding June 30, 2015 and December 31, 2014, respectively; (aggregate liquidation value of $353,042 and $352,626 at June 30, 2015 and December 31, 2014, respectively)||--||--|
|Common stock, $0.00001 par value:|
|Authorized: 80,000,000 shares at June 30, 2015 and December 31, 2014; 4,412,089 and 4,286,164 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively||--||--|
|Additional paid-in capital||321,071||318,420|
|Accumulated other comprehensive loss||(282)||(497)|
|Total stockholders' equity||27,544||49,827|
|Total liabilities and stockholders' equity||$ 57,878||$ 71,278|
|CONFORMIS, INC. AND SUBSIDIARIES|
|RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION|
|Reconciliation of Reported % Change to Constant Currency % Change|
|Three Months Ended June 30, 2015|
|Rest of World||24%||(30%)||54%|
|Reconciliation between GAAP and Non-GAAP Product Margin|
|Three Months Ended June 30,|
|Gross Profit (GAAP)||$8,558||$4,076|
|Product Gross Profit (Non-GAAP):||$5,099||$4,076|
|Gross Margin % (GAAP)||45%||36%|
|Product Gross Margin % (Non-GAAP)||32%||36%|
CONTACT: Investor contact Oksana Bradley email@example.com (781) 374-5598NEXT ARTICLE
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...